Evidence map›Paper›PMID 30629682›Full record

ArticlePloS one2019

Towards an understanding of C9orf82 protein/CAAP1 function.

Muhammad Assad Aslam, Mir Farshid Alemdehy, Colin E J Pritchard, Ji-Ying Song, Fitriari Izzatunnisa Muhaimin, Ruud H Wijdeven, Ivo J Huijbers, Jacques Neefjes, Heinz Jacobs

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Identification and Molecular Analysis of mAnimals : an open access journal from MDPI · 2022
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Muhammad Assad AslamDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Mir Farshid AlemdehyDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Colin E J PritchardMouse Clinic for Cancer and Aging research (MCCA) Transgenic Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Ji-Ying SongDivision of Experimental Animal Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Fitriari Izzatunnisa MuhaiminDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Ruud H WijdevenDepartment of Chemical Immunology, Leiden University Medical Center LUMC, RC Leiden, The Netherlands.
Ivo J HuijbersMouse Clinic for Cancer and Aging research (MCCA) Transgenic Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Jacques NeefjesDepartment of Chemical Immunology, Leiden University Medical Center LUMC, RC Leiden, The Netherlands.
Heinz JacobsDivision of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0001-6227-9850
The Netherlands Cancer Institute · NLLeiden University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

C9orf82 protein, or conserved anti-apoptotic protein 1 or caspase activity and apoptosis inhibitor 1 (CAAP1) has been implicated as a negative regulator of the intrinsic apoptosis pathway by modulating caspase expression and activity. In contrast, an independent genome wide screen for factors capable of driving drug resistance to the topoisomerase II (Topo II) poisons doxorubicin and etoposide, implicated a role for the nuclear protein C9orf82 in delaying DSBs repair downstream of Topo II, hereby sensitizing cells to DSB induced apoptosis. To determine its function in a genetically defined setting in vivo and ex vivo, we here employed CRISPR/Cas9 technology in zygotes to generate a C9orf82 knockout mouse model. C9orf82ko/ko mice were born at a Mendelian ratio and did not display any overt macroscopic or histological abnormalities. DSBs repair dependent processes like lymphocyte development and class switch recombination (CSR) appeared normal, arguing against a link between the C9orf82 encoded protein and V(D)J recombination or CSR. Most relevant, primary pre-B cell cultures and Tp53 transformed mouse embryo fibroblasts (MEFs) derived from C9orf82ko/ko E14.5 and wild type embryos displayed comparable sensitivity to a number of DNA lesions, including DSBs breaks induced by the topoisomerase II inhibitors, etoposide and doxorubicin. Likewise, the kinetics of γH2AX formation and resolution in response to etoposide of C9orf82 protein proficient, deficient and overexpressing MEFs were indistinguishable. These data argue against a direct role of C9orf82 protein in delaying repair of Topo II generated DSBs and regulating apoptosis. The genetically defined systems generated in this study will be of value to determine the actual function of C9orf82 protein.

Indexed as

DNA Breaks, Double-StrandedAnimalsApoptosisApoptosis Regulatory ProteinsB-LymphocytesCaspase 3Cell ProliferationCells, CulturedCRISPR-Cas SystemsDNA DamageDNA RepairDNA Topoisomerases, Type IIImmunoglobulin Class SwitchingMiceMice, Inbred C57BLMice, KnockoutApoptosis Regulatory ProteinsCaap1 protein, mouseCaspase 3DNA Topoisomerases, Type II

Identifiers

PMID30629682
PMCPMC6328148
OpenAlexW2910303273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.